OurPipeline*
Advancing Products Women Want
Advancing Products Women Want
We are committed to identifying, licensing or acquiring and developing candidates that expand options, improve outcomes and facilitate convenience for women. In addition to our lead products in development, our accelerator boasts a broad portfolio of diverse product candidates with first-in-category potential for women requiring or desiring new therapies in contraception, vaginal health, sexual health and fertility.
DARE-BV1^
Bacterial Vaginosis
Potential First-line Option for Bacterial Vaginosis
DARE-BV1 (bio-adhesive gel, clindamycin) is a potential front-line option for the treatment of bacterial vaginosis (BV). Thermosetting, prolonged-release antibiotic formulation aims to help treat once and done. Learn More.
Ovaprene®
Hormone-Free, Monthly Contraception
Partner: Bayer
First-in-category Hormone-Free, Monthly Contraception
Partner: 
Ovaprene (barrier IVR, ferrous gluconate) is designed to provide multiple weeks of contraceptive protection. Hormone-free, self-administered. Learn More.
Sildenafil Cream, 3.6%‡
Female Sexual Arousal Disorder
First-in-category for Treatment of Female Sexual Arousal Disorder
Sildenafil Cream, 3.6% (Topical Cream, Sildenafil) is a topical formulation specially made for women with female sexual arousal disorder, targeted to reach where it matters most. Learn More.
DARE-HRT1^‡
Hormone Replacement Therapy
First-in-category Sustained-Release Hormone Replacement Therapy
DARE-HRT1 (IVR, combination bio-identical estradiol + bio-identical progesterone) for hormone replacement therapy.
DARE-VVA1^
Vulvar and Vaginal Atrophy
(HR+ Breast Cancer Population)
First-in-category Treatment for VVA for ER/PR+ Breast Cancer Patients
DARE-VVA1 (vaginal insert, tamoxifen) is a proprietary formulation of tamoxifen for vaginal administration. Potential to be the first product specifically approved for the treatment of vulvar and vaginal atrophy (VVA) in patients with hormone-receptor positive (HR+) breast cancer.
DARE-FRT1^
Pregnancy Maintenance (PTB & ART)
First-in-category Sustained Release Progesterone for Pregnancy Maintenance
DARE-FRT1 (IVR, bio-identical progesterone) for the prevention of preterm birth and for fertility support as part of an IVF treatment plan.
Microchips
User-Controlled, Long-Acting Reversible Contraception
First-in-category, User-Controlled, Long-Acting, Reversible Contraceptive (UC-LARC)
A novel integrated drug/device technological approach to long-acting, reversible contraception. Learn More.
ORB 204/214^
6 & 12 Month Injectable Contraception
First-in-category 6 & 12 Month Injectable Contraception
A potential new injectable contraceptive that is designed to provide discreet, noninvasive, longer-acting reversible protection.
DARE-RH1
Non-Hormonal Male and Female Contraceptive Target
First-in-category Male or Female Contraceptive Target
A novel approach to male and female contraception.
^505(b)(2) regulatory pathway anticipated. *Ovaprene Post Coital Test (PCT) is a pre-pivotal clinical study.
‡HRT Phase 1 study to be conducted in Australia by Daré subsidiary.
*This timeline reflects management’s estimates as of August 30, 2019 and constitutes a forward-looking statement subject to qualifications under the Terms and Services of this website, including Section 13.4, Forward-Looking Statements; Disclaimer. Actual development timeline may be substantially longer, and Daré is under no obligation to update or review this estimate. “First-in-category” designation is a forward-looking statement based on management’s current expectations and currently available FDA-approved therapies.
Scientific
Publications*
Date
Details
Aug 8 – Aug 10, 2019
2019 Annual Meeting of the Infectious Diseases Society for Obstetrics and Gynecology
Location
Big Sky, Montana
Jul 22 – Jul 24, 2019
2019 Controlled Release Society Annual Meeting & Exposition
Location
Valencia, Spain
Determination of Drug Crystallinity in Hot Melt Extruded Ethylene Vinyl Acetate Copolymer
April, 2019
Journal of Pharmaceutical Sciences
Pharmacokinetics and Tolerability of a Novel 17b-Estradiol and Progesterone Intravaginal Ring in Sheep
March, 2019
Clinical and Experimental Obstetrics & Gynecology
Weekly vaginal administration of tamoxifen for three months in postmenopausal women with vulvar and vaginal atrophy: a possible new treatment approach?
Nov 4 – Nov 7, 2018
American Association of Pharmaceutical Scientists (AAPS) Annual Meeting: PharmSci 360
Location
Washington, DC
Pharmacokinetics and tolerability of a novel progesterone intravaginal ring in sheep
November-December, 2009
The Journal of Reproductive Medicine®
A Pilot Safety and Tolerability Study of a Nonhormonal Vaginal Contraceptive Ring
*Disclaimer: These publications have been prepared solely for illustration, educational and/or discussion purposes and are not intended to be relied upon for investment purposes. Under no circumstances should these publications or the information contained in them be used or considered as an offer, inducement, invitation, solicitation or recommendation to buy or sell any security or otherwise engage in any investment activity or as an expression of an opinion as to the present or future value or price of any security or financial instrument. Daré Bioscience does not guarantee the accuracy or completeness of any information appearing in third-party publications and is not liable for any delays, inaccuracies, errors in, or omissions from any such information, or for any actions taken in reliance on such information, or for any damages arising therefrom.